phosphoenolpyruvate has been researched along with Diabetic Nephropathies in 1 studies
Phosphoenolpyruvate: A monocarboxylic acid anion derived from selective deprotonation of the carboxy group of phosphoenolpyruvic acid. It is a metabolic intermediate in GLYCOLYSIS; GLUCONEOGENESIS; and other pathways.
phosphoenolpyruvate : A monocarboxylic acid anion resuting from selective deprotonation of the carboxy group of phosphoenolpyruvic acid.
phosphoenolpyruvic acid : A monocarboxylic acid that is acrylic acid substituted by a phosphonooxy group at position 2. It is a metabolic intermediate in pathways like glycolysis and gluconeogenesis.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gluconeogenesis increases in diabetic nephropathy (DN), escalating fasting and postprandial glucose levels." | 1.91 | PCK1 Protects against Mitoribosomal Defects in Diabetic Nephropathy in Mouse Models. ( Hasegawa, K; Sakamaki, Y; Tamaki, M; Wakino, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, K | 1 |
| Sakamaki, Y | 1 |
| Tamaki, M | 1 |
| Wakino, S | 1 |
1 other study available for phosphoenolpyruvate and Diabetic Nephropathies
| Article | Year |
|---|---|
PCK1 Protects against Mitoribosomal Defects in Diabetic Nephropathy in Mouse Models.
Topics: Albuminuria; Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2023 |